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Factors Influencing Depression Endpoints 
Research (FINDER) 
Results from the Belgian subgroup analysis
K. Schoevaerts1,4, K. De Bruyckere2, D. Quail3, K. Demyttenaere1
Objectives: To investigate the quality-of-life of patients in Belgium from the prospective, observational FINDER 
study of adult outpatients with depression initiating antidepressant medication.
Method: Here we report the post-hoc subgroup analyses of patients enrolled at Belgian sites.  Patients completed 
scales to assess quality of life, severity and chronicity of depression, anxiety and painful symptoms at baseline, 3 
months, and 6 months.   
Results: At baseline, 59.9% of 227 eligible Belgian patients had depression and 69.2% had anxiety. A higher HADS-A 
and SSI-Pain score and a lower SSI- Somatic score at baseline predicted lower odds of achieving remission. Higher 
baseline VAS scores were associated with the severity of nonpainful physical symptoms and previous depressive 
episodes.  The mean mental health score (SF-36 MCS) increased during follow-up, while the mean physical health 
score (SF-36 PCS) remained stable.
Conclusions: Physicians may not differentiate between depressive and anxiety symptoms when initiating antidepres-
sant treatment; anxiety may be a stronger predictor than depression for prescribing antidepressants. The presence 
of painful and nonpainful somatic symptoms may be predictors of treatment response in depression.
Key words: Depression – Anxiety - Observational study - Pain severity - Pain interference with functioning.
Introduction:
In psychiatry, a strong relationship is expected between diagno-
sis and prescription behaviour. However, this is not confirmed 
by the available literature. The ESEMeD study (The European 
Study on the Epidemiology of Mental Disorders) investigated 
the relationship between the diagnosis of depressive or anxiety 
disorders and the use of psychotropic medication (Demytte-
naere et al. 2008a). The study revealed that less than one-third 
of the subjects with a 12-month prevalence of major depressive 
disorder (MDD) and a number of subjects without any lifetime 
diagnosis of a psychiatric disorder were taking antidepres-
sants. The main predictors of the use of antidepressants were 
age and seeking help for emotional problems, rather than the 
presence of a formal Diagnostic and Statistical Manual, fourth 
edition (DSM-IV) diagnosis. This finding suggests that psycho-
tropic medication is not always prescribed in accordance with 
the approved indications.
Physicians do not always comply with the guidelines for diagno-
sis and treatment (Linden et al. 1999). One reason for this could 
be the limited ecological validity of the findings in antidepres-
sant randomised controlled trials (RCTs), which aim to achieve 
maximal homogeneity in the study population by using multiple 
inclusion and exclusion criteria. Strict inclusion criteria increase 
the likelihood that patients participating in RCTs are not repre-
sentative of the heterogeneous patient samples seen in daily 
practice (Yastrubetskaya et al. 1997). This could serve as an alibi 
for physicians to develop their own prescription behaviour.
Only about 14% of patients with MDD in routine practice 
would be eligible for inclusion in an RCT, with comorbidity 
being the main reason for exclusion (Zimmerman et al. 2002; 
Zimmerman et al. 2005; Keitner et al. 2003). A second reason 
for noncompliance of clinicians with the guidelines is the large 
group of patients presenting with subthreshold conditions (eg, 
minor depressive episode, recurrent brief depressive episode, 
subsyndromal symptomatic depression, and adjustment disor-
der with depressed mood) (Bauer et al. 2002; Cuijpers et al. 
2004). These conditions are highly prevalent and have a subs-
tantial impact on daily functioning (Judd et al. 2002). In view of 
the limited number of RCTs in these subthreshold depressive 
disorders, no evidence-based treatment recommendations can 
be given at present (Bauer et al. 2002). The WFSBP (World 
Federation of Societies of Biological Psychiatry) comments in its 
guidelines: “Close monitoring and problem solving therapy may 
be useful, and a treatment trial with one of the well-tolerated 
antidepressants is worth trying in more chronic and unremitting 
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6 months after commencing antidepressant medication (Bauer 
et al. 2008; Garcia-Cebrian et al. 2008; Reed et al. 2009).
This paper reports on the patients from the sites in Belgium 
enrolled in the FINDER study. First, we assessed the severity 
and prevalence of pain symptoms in this population. Second, 
we investigated the relationship between painful and nonpainful 
physical symptoms of depression and anxiety. Third, we exa-
mined the outcome in depression, anxiety, and pain following 
3- and 6-month naturalistic follow-ups, and we investigated 
predictive factors of outcome.
Method:
Here we report the post-hoc subgroup analyses of patients 
enrolled at Belgian sites in the FINDER study - a 6-month, mul-
ticentre, prospective, observational study conducted in 12 Eu-
ropean countries (Austria, Belgium, France, Germany, Ireland, 
Italy, The Netherlands, Norway, Portugal, Sweden, Switzerland, 
and the United Kingdom). The study was designed to provide 
more insight into the factors that may have an influence on HR-
QoL in clinically depressed nonhospitalised patients, initiating 
antidepressant treatment, in primary or secondary care (Bauer 
et al. 2008; Garcia-Cebrian et al. 2008; Reed et al. 2009).
In order to keep the study as naturalistic as possible, no struc-
tured diagnostic criteria were required for establishing the dia-
gnosis of depression. The aim of the study was non-interven-
tional, which means that all treatment decisions were at the 
discretion of the participating physician.
Assessments were performed at baseline, at 3 months (±1 
month), and at 6 months (±1 month) during the follow-up pe-
riod. At baseline, data were collected on patient sociodemogra-
phics and psychiatric history. Investigators recorded whether 
there was a history of comorbid chronic medical or functional 
conditions, use of medication, and psychotherapeutic counse-
ling.
The detailed study design and the methods have already been 
reported elsewhere (Garcia-Cebrian et al. 2008; Demyttenaere 
et al. 2010; Demyttenaere et al. 2009) and are only briefly des-
cribed here. The study was approved in all countries according 
to local requirements for ethics and/or regulatory approvals for 
observational studies, and all patients provided written infor-
med consent.
Psychometric instruments
Symptom scales collected at baseline, 3 months, and 6 
months follow-up.
The symptom scales used in this study assessed both emotional 
and somatic symptoms.
cases” (Bauer et al. 2002). Logically, this may result in off-label 
prescriptions for antidepressants.
It has been shown that many patients do not present just 1 
psychiatric condition but rather report depressed, anxious, and 
painful (somatic) symptoms concurrently that may or may not 
reach the threshold of comorbidity (Lowe et al. 2008).
Epidemiological studies show that the prevalence of chronic 
painful physical symptoms is increased in patients with a de-
pressive disorder and in patients with anxiety disorders. This in-
dicates that these pain symptoms are not specific to depressive 
disorders (Ohayon et al. 2003; Aaronsen et al. 1998; Demytte-
naere et al. 2008b; Demyttenaere et al. 2006).
Comorbid chronic painful physical symptoms result in poorer 
recognition of depression, (Kirmayer et al. 1993) and in lower 
remission figures (Ohayon et al. 2003). This may be due to se-
veral factors, including less tendency to seek help, and longer 
delays before seeking help for depressive symptoms in com-
bination with pain symptoms, (Demyttenaere et al. 2006) or a 
lower efficacy of antidepressants on painful physical symptoms.
The effect size measured after 9 months of treatment with 
antidepressants is lower for painful (and nonpainful) depressive 
somatic symptoms, compared to nonsomatic depressive symp-
toms (Greco et al. 2004). During antidepressant treatment, 
responders (in remission or not) experienced significantly more 
change in both painful and nonpainful physical symptoms com-
pared to nonresponders. This suggests that the changes in the 
nonpainful and painful physical symptoms occur in parallel with 
each other (Greco et al. 2004).
In addition, proof of the relevance of physical symptoms in de-
pression and anxiety is, for example, the finding that in patients 
with myocardial infarction or chronic heart failure, the somatic 
symptoms which are associated with or which are part of de-
pression not only influence the outcome of depression but also 
the somatic/affective symptoms of depression are even more 
predictive of mortality than the cognitive/affective symptoms of 
depression (deJonge et al. 2006; Schiffer et al. 2009).
Although recent literature is more focused on the “comorbi-
dity” of depression and anxiety, and of depression and painful 
physical symptoms, the relationship between these clusters of 
symptoms (including the nonpainful physical symptoms) is not 
fully understood. Therefore, the specificity of the comorbidi-
ty between somatoform clusters and other mental disorders 
should be further investigated (Lieb et al. 2007).
Pain, like many somatic symptoms, is a subjective experience 
(from sensory to affective, cognitive, and behavioural aspects). 
Therefore, it is important to investigate not only the severity of 
pain but also the interference of pain with functioning in daily 
life in patients with a depressive episode.
The FINDER (Factors Influencing Depression Endpoints Re-
search) study was a European, multicentre, prospective, obser-
vational study investigating health-related quality-of-life (HR-
QoL) outcomes in an adult population with a clinical diagnosis of 
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isof pain in daily life according to VAS were “not at all” to “totally 
debilitating”. Moderate to severe interference of pain in daily 
life was defined as a score >30 mm.
Health-related quality of life at baseline, at 3 months, 
and at 6 months follow-up.
Heath-related quality of life (HRQoL) was assessed by using the 
36-item Short Form Health Survey (SF-36) (Ware et al. 1993). 
The SF-36 is a questionnaire, originally in English, validated in 
Dutch (Aaronsen et al. 1998) and French (Leplege et al. 1998), 
that consists of 36 questions generating scores across 8 health 
domains (4 mental and 4 physical subscales) and 2 summary 
scores (the Physical Component Score [PCS] and the Mental 
Component Score [MCS]). Within each subscale, the scores on 
the individual items are summed and transformed to a scale of 
0 to 100. A higher score indicates a better quality of life. The 
SF-36 subscales were normalised to a mean of 50 (standard de-
viation [SD] 10) for the general United States adult population. 
Any score below 50 suggests a HRQoL below the average of 
the standardised population (Ware et al. 2001).
Sociodemographic variables and psychiatric history at 
baseline.
The following sociodemographic variables were collected: age, 
gender, education (none or mandatory compared to further 
education), marital status (married/domestic partner or other), 
occupational status (employed, unemployed, or other), num-
ber of dependants, body mass index (BMI), and smoking status. 
The following clinical variables were also collected: duration of 
the current depressive episode, number of previous depressive 
episodes, age at which the first depressive episode occurred, 
psychiatric comorbidity within the 2 years prior to inclusion, 
and the presence of a chronic medical condition.
Statistical method
All patients enrolled at a Belgian site, who were eligible for the 
FINDER study and who had completed the HADS at baseline, 
were included in this post-hoc analysis.
Counts and percentages of patients falling within the defined 
diagnostic categories at baseline were calculated, and suitable 
summary statistics were applied to the different patient cha-
racteristics.
Differences between the diagnostic categories and within the 
2 pain groups (none to mild/moderate to severe according to 
VAS for pain) are presented descriptively. For patients with fol-
low-up data on the HADS, percentages of still caseness and of 
patients with remission, as defined above, were calculated.
For each of the 3 baseline categories (caseness for depression, 
caseness for anxiety, and caseness for comorbid depression and 
anxiety), logistic regression analyses were performed to model 
each of the log odds of still caseness and of remission, by using 
backward elimination methods.
The Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS) (Zigmond 
et al. 1983; Spinhoven et al. 1997; Friedman et al. 2001) is a well-
known and well-documented screening instrument for anxiety 
and depression. The HADS consists of 7 items for depression 
and 7 items for anxiety and evaluates how the patient felt during 
the week prior to completing the questionnaire. Each item is 
scored on a 4-point scale from 0 to 3, leading to scores on the 
subscales for anxiety and depression (respectively HADS-A and 
HADS-D) from 0 to 21. For both subscales, a score of 0 to 7 can 
be regarded as a noncase of anxiety (HADS-A) or depression 
(HADS-D); a score of ≥11 is indicative of a probable case, and 
scores between 8 and 10 indicate doubtful cases.
Possible combinations of scores on the subscales (for anxiety: 
noncase [A-], doubtful case [A?], and probable case [A+]; for 
depression: noncase [D-], doubtful case [D?], probable case 
[D+]) were matched with the more commonly used DSM-IV 
diagnostic categories and defined according to the following 5 
subgroups (Demyttenaere et al. 2009): 
1. Noncaseness, no anxiety disorder, no depressive disor-
der: D-A-, D-A?, or D?/A-
2. Mixed anxiety-depression: D?A? (subthreshold depres-
sive and anxiety symptoms)
3. Caseness for depression: D+A- or D+A?
4. Caseness for anxiety: D-A+ or D?A+
5. Caseness for comorbid depression and anxiety: D+A+
All patients with complete HADS ratings at baseline, at 3 
months, and at 6 months were classified according to these dia-
gnostic categories.
Remission, traditionally defined as achieving a status with no 
significant symptomatology, was defined as D-A- at 3 months 
and 6 months (Demyttenaere et al. 2009) irrespective of the 
caseness status at baseline. 
28-item Somatic Symptom Inventory 
Somatic (painful and nonpainful) symptoms were scored with 
the 28-item Somatic Symptom Inventory (SSI-28) (Barsky et 
al. 1986). The SSI is a patient self-report questionnaire that 
assesses the extent to which different somatic symptoms are 
experienced as bothersome during the past week. Each com-
plaint is rated on a defined scale from 1 (not at all) to 5 (very 
much). The pain subscale (SSI-Pain) is derived by calculating the 
mean score of 7 pain-related items. The somatic subscale (SSI-
Somatic) consists of the remaining 21 items.
Visual Analogue Scale for Pain
The overall pain severity was represented on a visual analogue 
scale (VAS), rated from the extremes of experiencing ‘no pain’ 
(0 mm) to experiencing pain “as severe as I can imagine” (100 
mm). A cutoff score of >30 mm was used to distinguish no 
or mild pain from moderate to severe pain (Kelly et al. 2001; 
Collins et al. 1997). The corresponding anchors for interference 
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odds ratios. The 95% confidence intervals are presented for all 
statistically significant (p ≤ 0.05) independent variables in the 
model.
Multivariate regression analysis was performed to identify va-
riables independently associated with severity of overall pain 
(overall pain VAS) at baseline (Demyttenaere et al. 2010). 
More detailed information on the statistical methods is found 
in previous publications about the FINDER study (Bauer et al. 
2008; Garcia-Cebrian et al. 2008; Reed et al. 2009; Demytte-
naere et al. 2010).
Results
Results at baseline
Patient recruitment started in May 2004 and completed in Sep-
tember 2005.
Adult patients (Europe, n= 3468; Belgium n= 239) were eli-
gible for inclusion if they were diagnosed as suffering from 
depression by their attending physician (psychiatrist) (Europe, 
n= 1818; Belgium, n= 104) or general practitioner (Europe, 
n= 1650; Belgium, n=135) and if antidepressant treatment was 
about to be initiated for a first depressive episode or for a new 
episode of recurrent depression.
In total, 227 eligible Belgian patients with nonmissing scores for 
both HADS-A and HADS-D were included. Of these eligible 
patients, 67% were female and 33% were male. The mean age 
was 45.9 years old. The youngest patient was 18 years old; the 
oldest patient was 84 years old. 
Subgroups and diagnostic categories based on HADS at 
baseline.
The distribution of the 227 patients based on the HADS for 
respectively each subgroup and each diagnostic category (status 
for depression: noncase, doubtful case, probable case; and sta-
tus for anxiety disorder: noncase, doubtful case, probable case) 
is presented in Tables 1 and 2. Caseness for depression was 
present in 59.9% of the patients, irrespective of anxiety, and 
caseness for anxiety was present in 69.2% of the patients, irres-
pective of depression. In total, 15.4% did not meet the criteria 
of a depressive or anxiety disorder.
We noted different ratios in the subgroups according to the 
specialty of the investigator.  For general practitioners, a pro-
bable case for depression was found in 56.2% of patients com-
pared to 65% of the patients for psychiatrists. For comorbid 
depression and anxiety this was 50% of patients from general 
practitioners and 49.5% of patients from psychiatrists and for a 
probable case for anxiety this was 70% of patients from gene-
ral practitioners and 68% of the patients, from psychiatrists. 
No depressive or anxiety disorder was found in 17.7% of the 
patients from general practitioners and in 12.4% of the patients 
from psychiatrists.
Table 1: Distribution of all patients from Belgian sites 
included in the analysis according to HADS subgroups 
at baseline
% of all patients 
(n=227)
Non-case for 
depression 
D- (%)
Doubtful case 
for depression 
D? (%)
Probable case 
for depression 
D+ (%)
Non-case for 
anxiety A-(%)
6.2 2.6 2.6
Doubtful case for 
anxiety A? (%)
6.6 5.3 7.5
Probable case for 
anxiety A+ (%)
7.5 11.9 49.8
HADS = Hospital Anxiety and Depression Scale. Overall ca-
seness for depression (irrespective of anxiety) = 59.9%; Ove-
rall caseness for anxiety (irrespective of depression) = 69.2%.
Table 2: Distribution of all patients from Belgian sites 
included in the analysis according to HADS diagnostic 
categories at baseline
HADS 
diagnostic 
category
Non-
caseness 
for anxiety 
and 
depression 
D-A- D-A? 
D?A-
Mixed 
anxiety-
depression 
D?A?
Caseness 
for 
depression 
D+A- 
D+A?
Caseness 
for anxiety 
disorder 
A+D- 
A+D?
Case-
ness for 
comorbid 
depres-
sion-
anxiety 
D+A+
% of all 
patients 
(n=227)
15.4 5.3 10.1 19.4 49.8
HADS = Hospital Anxiety and Depression Scale
Severity of painful and nonpainful somatic symptoms at 
baseline according to diagnostic category.
Moderate to severe clinically relevant pain scored on the VAS 
(VAS >30 mm), occurred in 57.5% of the patients. 50.0% of 
patients experienced a clinically relevant interference of their 
pain symptoms in daily life.
Clinically relevant pain (scored on both the VAS for pain severity 
measure and the SSI-Pain for bothersomeness) occurred most 
frequently in the comorbid depression and anxiety diagnostic 
category. On the VAS, 66.7% of the comorbid depression and 
anxiety diagnostic category had a score higher than 30 mm, 
accounting for moderate to severe pain. Likewise, this pattern 
is confirmed for the SSI-Pain, with the highest mean pain score 
found in the comorbid group (SSI-Pain mean score: 2.7). The-
refore, painful somatic symptoms seem to increase with seve-
rity of the psychopathology. For nonpainful somatic symptoms 
(scored on the SSI-Somatic), we note a similar relationship with 
the severity of the psychopathology, with the greatest bother-
someness also in the comorbid group (SSI-Somatic mean score: 
2.6). Table 3 shows the severity of the somatic symptoms ac-
cording to HADS diagnostic categories at baseline.
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isThe regression analysis of the VAS overall pain score at baseline 
as the dependent variable demonstrates that the severity of the 
nonpainful physical symptoms (as measured by the SSI-Soma-
tic score) was the variable most strongly associated with the 
baseline severity of pain, in addition to having a painful medical 
condition and having fewer previous depressive episodes being 
predictive of pain severity (Table 4).
Table 4: Independent variables significantly associated 
with pain severity (VAS) at baseline
Independent 
variable
Estimate F value P value
Pain severity 
(VAS)
SSI-Somatic 
score
13.9 33 <0.0001
Medical 
condition
11 <0.0001
Painful 18.6
Non-painful 9.8
Number 
of previous 
depressive 
episodes
-4.2 6.1 0.015
VAS = Visual Analogue Scale; SSI = Somatic Symptom Inventory
Table 3: Severity of somatic symptoms according to 
HADS diagnostic categories at baseline
All 
patients 
(N=227)
Non-
caseness 
for 
depression 
and 
anxiety
Mixed 
anxiety-
depression
Caseness 
for 
depression
Caseness 
for anxiety
Case-
ness for 
comorbid 
depres-
sion-
anxiety
SSI-Pain 
score, 
mean (SD)
2.1 (0.7) 1.7 (0.5) 2.2 (0.7) 2.4 (0.9) 2.7 (0.9)
SSI-Somatic 
score, 
mean (SD)
1.7 (0.4) 1.7 (0.4) 2.2 (0.5) 2.1 (0.6) 2.6 (0.7)
VAS-Pain 
score 
>30 mm 
(moderate 
to severe 
pain) (%)
47.1 25.0 54.6 59.5 66.7
For SSI and VAS: higher figures indicate worse scores.  HADS = 
Hospital anxiety and depression Scale; SD = standard deviation; 
SSI = Somatic Symptom Inventory; VAS = Visual Analogue Scale
Figure 1 presents the distribution of the patients for VAS pain 
scores (a) and for interference of pain with functioning (b) at 
baseline and at 6 months.
Figure 1: Distribution of patients for VAS for a) overall pain severity, and b) interference of pain with functioning
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Results at Follow-up
Remission and still caseness (persistence of pathology) 
at 3 and 6 months follow-up.
Table 6 illustrates remission rates at 3 and 6 months follow-
up. At 3 months, 213 patients were still in follow-up compared 
to 208 patients at 6 months. Remission rates at 6 months fol-
low-up were clearly higher than at 3 months follow-up in the 
caseness for anxiety group (27% and 16.2%, respectively) and 
in the comorbid anxiety-depression group (34.7% and 11%, 
respectively). This correlation between longer duration and 
better outcome was not observed in the caseness for depres-
sion group, for which lower remission rates were found at 6 
months compared to 3 months follow-up (31.6% and 42.1%, 
respectively).
In addition, it is noteworthy that, respectively, 36.8%, 40.5%, 
and 40% of the patients with caseness for anxiety, depression, 
and comorbid anxiety-depression at baseline still met the crite-
ria for caseness after 6 months. 
Baseline factors associated with remission at 6 months follow-up.
A logistic regression analysis was conducted of all patients for 
evaluating remission at 6 months follow-up including all base-
line variables as possible predictors. A higher baseline HADS-A 
score, a higher SSI-Pain score, and a lower SSI-Somatic score 
predicted lower odds of achieving remission (Table 7).
Table 7: Logistic regression analysis for remission at 6 
months with baseline variables as possible predictors
All patients 
(N=227)
Odds Ratio Pr > ChiSq
Effect
Point 
Estimate
95% Wald Confidence 
Limits
HADS-A 0.884 0.81 0.965 0.006
SSI-Somatic 1.994 1.076 3.695 0.0284
SSI-Pain 0.587 0.366 0.941 0.0271
Table 5: Health-related quality of life according to HADS diagnostic categories at baseline
 All patients (N=227)
Non-caseness for 
depression and 
anxiety, mean 
(SD)
Mixed anxiety-
depression, mean 
(SD)
Caseness for 
depression, mean 
(SD)
Caseness for 
anxiety, mean 
(SD)
Caseness for 
comorbid 
depression-
anxiety, mean 
(SD)
Mental Health summary score (transformed score), 
mean (SD)
35.7 (10.0) 25.6 (7.6) 22.5 (8.1) 26.4 (7.6) 17.9 (7.0)
Physical Health summary score  
(transformed score), mean (SD)
48.1 (9.1) 52.9 (10.1) 43.1 (9.9) 46.7 (9.1) 42.7 (9.2)
Normative mean (SD): 50 (10).  Lower figures indicate worse scores.  HADS = Hospital Anxiety and Depression Scale; SD = 
standard deviation; SF-36 = 36-item Short Form Health Survey
Health-related quality of life (SF-36) according to dia-
gnostic categories at baseline.
The mean physical health score (PCS) in the study population 
was only slightly lower compared to population norms (from 
about 0.2 SD in the noncaseness subjects without depressive 
or anxiety disorder to 0.7 SD in the subjects with comorbid 
anxiety and depression). On the other hand, the mean mental 
health score (MCS) was markedly impaired compared to popu-
lation norms (from about 1.4 SD in the noncaseness subjects to 
3.2 SD in the comorbid anxiety-depression subjects). Table 5 
illustrates HRQoL (SF-36) according to HADS diagnostic cate-
gories at baseline.
Table 6: Remission rates at 3 and at 6 months follow-up
A. Caseness for depression at baseline (N=227)
Follow-Up
Still caseness (persistence 
of pathology) (D+A+, 
D+A-, D+A?) (%)
Remission (D-A-) (%)
3 months 26.3 42.1
6 months 36.8 31.6
B. Caseness for anxiety at baseline (N=227)
Follow-up
Still caseness (persistence 
of pathology) (D+A+, 
D-A+, D?A+) (%)
Remission (D-A-) (%)
3 months 51.4 16.2
6 months 40.5 27.0
C. Caseness for comorbid depression-anxiety at baseline (N=227
Follow-up
Still caseness (persistence 
of pathology) (D+A+, 
D?A+, D-A+, D+A?, 
D+A-) (%)
Remission (D-A-) (%)
3 months 63.0 11.0
6 months 40.0 34.7
For anxiety: noncase = A-; doubtful case = A?; probable case 
= A+. For depression: noncase = D-; doubtful case= D?; pro-
bable case = D+.
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isTable 9: Health-related quality of life at baseline, 3 
months, and 6 months (overall patient population).
Health-related Quality 
of Life
 Study Period
Mean (SD) of 
Standardized Score 
Mental Health summary 
score (transformed score)
baseline 23.2 (10.0)
3 months 33.7 (11.7)
6 months 38.4 (12.2)
Physical Health summary 
score (transformed score)
baseline 45.1 (9.6)
3 months 46.8 (8.6)
6 months 48.7 (8.4)
Discussion
Within this naturalistic study of patients, a first interesting 
finding is that almost 60% of the patients enrolled at Belgian 
sites with a clinical diagnosis of depression, whose attending 
physician decided to initiate antidepressant treatment, were 
probable cases for depression, with the vast majority having a 
comorbid anxiety disorder. This does not imply that the other 
40% did not have any psychiatric condition; half of these did 
show probable caseness for anxiety disorder. Remarkably, wit-
hin the total group of patients included in this analysis, more 
patients had caseness for anxiety (69.2%) than for depression 
(59.9%) (Tables 1 and 2). 
These findings suggest that, in daily clinical practice, physicians 
do not always make a differential diagnosis between depressive 
and anxiety disorders when initiating antidepressant treatment, 
and that anxiety is present in a high proportion of patients recei-
ving antidepressants. It has been shown previously that physi-
cians use other methods to make prescription decisions instead 
of basing their decision on the formal DSM-IV or ICD-10 crite-
ria (Linden et al. 1999). 
In this post-hoc analysis of patients enrolled from Belgian sites, 
caseness for comorbid anxiety-depression was found in 49.8% 
of the patients. Previously published results reveal that depres-
sion and anxiety comorbidity varies between 39% (in an Austra-
lian national study evaluating mental health [Hunt et al. 2004]), 
and 59% (in a German national study [Carter et al. 2001]), and 
between 51% and 62% in depressed outpatient samples (Rush 
et al. 2005; Fava et al. 2000).
Nearly 21% of patients had no formal psychiatric diagnosis of 
anxiety or depressive disorder according to their self-reported 
symptomatology (Table 2). This does not exclude having any 
sign at all of a mental disorder. The accurate prescription of 
antidepressants has been discussed above (Demyttenaere et 
al. 2008a; Linden et al. 1999). A Finnish study (Joukamaa et al. 
1995) within primary care revealed that psychotropic medi-
cation was prescribed in 70% of patients with symptoms of a 
mental disorder (a wider definition than a formal diagnosis) and 
in 13% of patients with no obvious sign of a mental disorder. 
HADS-A = Hospital Anxiety and Depression Scale – Anxiety; 
SSI = Somatic Symptom Inventory.
Severity and interference in daily functioning of the painful somatic 
symptoms and associated variables.
Looking at pain severity, 72.8% of the patients scored below 
the cutoff for moderate to severe pain (VAS >30 mm) at 6 
months (as opposed to 41% at baseline). Considering interfe-
rence of pain in daily life, 78.2% of the patients scored below 
the cutoff score (VAS >30 mm) at 6 months (as opposed to 
48.7% at baseline) (Figure 1).
A higher pain severity measurement at the 6 months follow-
up was significantly associated with the presence of a higher 
pain severity measurement at baseline, a higher baseline seve-
rity score of the nonpainful physical symptoms, by the class 
of administered analgesics between baseline and the 3-month 
assessment, by a lower severity of depression at baseline, and 
by the presence or nonpresence of a painful medical condition 
at baseline (Table 8).
Health-related quality of life (SF-36) at baseline, at 3 months, and 
at 6 months follow-up.
The mean mental health score (SF-36 MCS) increased during 
follow-up. The mean score for the whole patient group was 
23.2 at baseline, 33.7 at 3 months, and 38.4 at 6 months. The 
mean physical health score (SF-36 PCS) remained rather stable 
over the whole follow-up period, with a mean score of 45.1 at 
baseline and 48.7 at 6 months. See Table 9 for HRQoL (SF-6) at 
baseline, 3 months, and 6 months.
Table 8: Independent variables at baseline significantly 
associated with the severity of overall pain at 6 months 
Independent variable Estimate F value P value
Severity of 
overall pain 
(VAS)
Pain severity (VAS) 0.3 26 <0.0001
SSI-Somatic score 9.3 17 <0.0001
Class of analgesics  8 <0.0001
Basic 9.8   
NSAID 12.9   
Opioids 20.1   
HADS-D -1.2 15 <0,001
Medical condition  5 0.007
Painful 11.2   
Non-Painful 3.9   (NS)
Analgesics used during the observation period from baseline to 
3 months.  VAS = Visual Analogue Scale; HADS-D = Hospital 
Anxiety and Depression Scale - Depression; NSAID = nonste-
roidal anti-inflammatory drug; SSI = Somatic Symptom Inven-
tory; NS= Non Significant
n
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months, since a great part of the pain severity at baseline was 
probably associated with the severity of the depressive psycho-
pathology at baseline. In addition, it has been shown that effec-
tive pain reduction with antidepressant treatment is partly due 
to a direct effect and partly via an improvement of depressive 
symptomatology (Dworkin et al. 2007; McCleane 2008).
The mean mental health score (SF-36) at baseline was much 
lower compared to the standard population norm, in contrast 
to the more stable physical health score. It is noticeable that 
the lower mean mental health score was observed at baseline 
even in the group of patients where no diagnosis was esta-
blished (D-A-, D-A?, D?A-) (Table 5). This suggests that these 
help-seeking patients really do present with a substantial loss 
of emotional quality of life, even though they do not meet the 
caseness criteria for depression or anxiety disorder. The finding 
that the lowest mental health score of the SF-36 was observed 
in the comorbid depression-anxiety group at baseline confirms 
previously published results of functional limitation within 
this subgroup (Boulenger et al. 1997; Judd et al. 1998) and of 
a lower mental health score in this subgroup compared to a 
pure generalised anxiety disorder or a pure depression (Carter 
et al. 2001). In addition, the fact that the mean mental health 
score increases at 3 months and 6 months follow-up evalua-
tions indicates an increase in mental HRQoL when depressive 
and anxiety symptoms decrease. For the whole patient sample, 
the mental health score at 6 months was still 1 SD below the 
standard population norm.
Within the 3 diagnostic categories (caseness for depression, 
caseness for anxiety, and caseness for comorbid depression and 
anxiety) remission rates of approximately 30% were noted at 
6 months follow-up. These rather low remission rates can be 
due to the presence of residual depressive symptoms leading to 
continued impairment. For patients with caseness for anxiety 
and those with caseness for comorbid depression-anxiety, a 
better symptomatic outcome was reported with more long-
term treatment (6 months compared to 3 months) (Table 6). 
this correlation was not present in the caseness for the depres-
sion group, considering the greater remission rates at 3 months 
compared to 6 months. This finding is in contrast to the one 
from the European data (Demyttenaere et al. 2009) demons-
trating a positive correlation between treatment outcome and 
treatment duration for all 3 diagnostic categories. At 3 months, 
the remission rates for the depression caseness group were 
higher than those of the caseness for anxiety group or of the 
comorbid group. At 6 months, this difference among the groups 
seems smaller.(Table 6). Therefore, in this analysis, there was 
no large difference in remission rates after 6 months between 
patients with caseness for depression (rate of 31.6%) and those 
with caseness for comorbid depression and anxiety (rate of 
34.7%), unlike the European FINDER data which demonstra-
ted a difference in outcome between the diagnostic categories, 
with 10% lower remission rates for the comorbid group. These 
results should be seen in light of an ongoing debate on the ques-
tion of whether remission rates in patients with depression and 
The percentage of patients not meeting the criteria of a depres-
sive or anxiety disorder and who are prescribed antidepressant 
medication, nevertheless, is greater in the group treated by the 
general practitioner compared to the group treated by the psy-
chiatrist. The findings are consistent with previously published 
data (Mojtabai 1999).
A second important finding in this naturalistic study is the pre-
sence of moderate to severe pain in more than half of the pa-
tients within our population seeking help and of interference 
of pain in daily life in about half the patients (Fig. 1). This is 
consistent with previously published data regarding the rela-
tionship between depression or anxiety and more chronic pain 
(Ohayon et al. 2003; Demyttenaere et al. 2006; Bair et al. 2003; 
Bair et al. 2004). Both pain and interference of pain decreased 
during follow-up.
The finding that pain symptoms and severity of pain (on SSI-
Pain and on VAS-Pain) increase with the severity of the psy-
chopathology confirms that patients with a depressive disorder 
or with an anxiety disorder experience more painful somatic 
symptoms (Demyttenaere et al. 2008b; Demyttenaere et al. 
2006; McWilliams et al. 2004; Sartorius et al. 1993). 
A third interesting finding is that the nonpainful somatic symp-
toms (SSI-Somatic) follow the same pattern (Table 3). This sug-
gests that their relationship with depression and anxiety is simi-
lar to the relationship of pain symptoms with depression and 
anxiety. These findings support recently published data claiming 
that scores on the SSI-Pain (headache, low back pain, muscle 
stiffness, neck pain, and joint pain), as well as scores on the non-
painful SSI items (SSI-Somatic: fatigue, the feeling of not being in 
good general health, not feeling well, feeling weak, a feeling of 
heaviness in arms and legs, cold hands and feet) increase signifi-
cantly in patients with major depression (Vaccarino et al. 2008). 
Previous studies have demonstrated that the presence of pain 
symptoms compromises the outcome of antidepressant treat-
ment (Ohayon et al. 2003; Bair et al. 2003; Bair et al. 2004). 
The present findings suggest that nonpainful physical symptoms 
should probably also be taken into account as possible predic-
tors of treatment response in depression (Reed et al. 2009).
The association between painful physical symptoms and non-
painful physical symptoms may suggest that they are better 
understood as 1 group of somatoform or somatic symptoms 
instead of focusing separately on the 1 (painful) or the other 
(nonpainful) subgroup. Standardised rating scales for somatic 
symptoms (like the SSI, Patient Health Questionnaire-somatiza-
tion subscore, or the Symptom Check List-somatization subs-
core) currently cluster both painful and nonpainful symptoms 
into 1 group of symptoms. 
A fourth interesting finding is that a higher score on the HADS-
D at baseline is associated with a lower severity of the pain 
symptoms at 6 months. This seems a rather counterintuitive 
result (Table 8). It has been documented that the reported 
pain severity is partly determined by the severity of depression 
(Shelton et al. 2007). This explains why patients with a higher 
n
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isadditional anxiety symptoms are lower compared to patients 
with depression without anxiety symptoms (Nelson 2008). Part 
of the discussion is probably to be understood in view of the use 
of different definitions of anxious depression within different 
studies, albeit not explaining it entirely. In STAR*D (Sequenced 
Treatment Alternatives to Relieve Depression), remission 
rates in nonanxious depression compared to anxious depres-
sion were 33.4% and 22.2%; respectively; remission rates in 
patients without or with generalised anxiety disorder were 
29.5% and 21.2%, respectively (Fava et al. 2008; Trivedi et al. 
2006). This 10% difference in remission rates corresponds with 
the European data of the FINDER study (Demyttenaere et al. 
2009). 
One could expect a higher baseline HADS-A score and a higher 
baseline SSI-Pain score to predict lower odds of obtaining re-
mission (Demyttenaere et al. 2009;Trivedi et al. 2006) (Table 7). 
Consequently, given the strong correlation between SSI-Soma-
tic and SSI-Pain, it was a rather unexpected finding that a lower 
SSI-Somatic score was predictive of lower remission rates.
This study has a number of important limitations that affect the 
interpretation and generalisability of the study results. First, 
the study population is small (n= 227). Although most findings 
correspond with those found in the larger European database 
(Demyttenaere et al. 2009), some were contradictory. 
Second, several variables (length of depressive episode, history 
of past episodes, somatic comorbidity, etc.) were collected via 
medical records, patient reports, and a clinical interview, rather 
than via a standardised diagnostic interview. 
Third, the HADS-based diagnostic categories were constructed 
in order to approach more standardised diagnostic categories. 
However, the European study (Demyttenaere et al. 2009) re-
veals that the results closely reflect those of other studies that 
used more standardised diagnostic categories. 
Fourth, the data on intensity and interference of pain are limited 
to the past week. Pain is a complex matter, and more detailed 
information on the duration of pain, or its location, could be of 
added value in the study. However, the total pain experience 
can never be completely understood via questionnaires. 
Fifth, the observation period was limited to 6 months. At 6 
months, about one-third of the patients reported persistence 
of moderate to severe pain. A longer follow-up period could 
have revealed a subgroup with refractory pain and depression. 
Finally, in analogy to the VAS for pain, a VAS for interference of 
pain in daily life was used, and no significant cutoff score for this 
instrument has been reported so far in literature. It was used 
only descriptively in the analyses of this study and has a good 
face validity.
We conclude that physicians do not always differentiate between 
depressive and anxiety disorder symptoms when initiating an-
tidepressant medication and that anxiety seems a stronger pre-
dictor than depression for prescribing antidepressants. Second, 
we conclude that there is a high correlation between nonpainful 
somatic symptoms, painful somatic symptoms, depression, and 
anxiety disorder. These findings may contribute to the discus-
sion on the future classification of somatic (painful and non-
painful) symptoms in patients with a depressive and/or anxiety 
disorder. Third, we conclude that the majority of patients with 
a depressive and/or anxiety disorder only have partial or no res-
ponse to a treatment with antidepressants. 
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Objectifs:
Examiner la qualité de vie des patients belges dans l’étude pros-
pective et observationnelle de FINDER, dans laquelle des patients 
adultes et ambulatoires souffrant de dépression prennent un trai-
tement  d’antidépresseurs.
Méthode:
Dans cet article, nous rapportons l’analyse du sous-groupe post-
hoc de patients inclus en Belgique. Les patients ont rempli des 
questionnaires à fin d’ évaluer la qualité de vie ainsi que la gravité 
et la chronicité de la dépression, de l’anxiété et des symptômes de 
douleur, ceci au point de départ, à 3 mois et à 6 mois.
Résultats:
Au départ, 59.9% des 227 patients souffraient de dépression et 
69.2% d’anxiété. Un score élevé pour le HADS-A et pour le SSI-
Pain et un faible score pour le SSI-somatique au départ prédisaient 
moins de chance de rémission. Un score élevé pour le VAS au point 
de départ était associé à la gravité des symptômes physiques de 
non-douleur et des épisodes dépressifs précédents. Le score de 
santé mentale moyen (SF-36 MCS) a augmenté au cours du suivi, 
alors que le score de santé physique moyen (SF-36 PCS) est resté 
stable.
Conclusions:
Les médecins ne font pas de distinction entre les symptômes de 
dépression et d’anxiété lorsqu’ils initient un traitement par antidé-
presseurs. L’anxiété se révèle être un facteur prédictif plus puissant 
que la dépression pour la prescription d’antidépresseurs. La pré-
sence de symptômes somatiques de douleur et de non douleur per-
met de prédire la réponse aux antidépresseurs dans la dépression
Mots-clés: Dépression - Anxiété - Etude observationnelle – Sévérité 
de la douleur - Impact de la douleur avec le fonctionnement.
Résumé
Doelstellingen:
Het onderzoeken van de levenskwaliteit van Belgische patiënten in 
de prospectieve, observationele studie FINDER waarin bij volwas-
sen, ambulante patiënten met een depressie antidepressieve medi-
catie wordt gestart. 
Methode:
In dit artikel rapporteren we de post-hoc subgroep-analyses van 
patiënten geïncludeerd in België. Patiënten vulden vragenlijsten in 
om de levenskwaliteit, de ernst en duur van depressieve en angst-
symptomen en pijnsymptomen in kaart te brengen, zowel op base-
line, na 3 maanden als na 6 maanden. 
Resultaten:
Op baseline hadden 59.9% van de 227 patiënten een depressie en 
69.2% een angststoornis. Een hogere HADS-A en SSI-PAIN score 
en een lagere SSI-Somatic score bij baseline voorspelde een lagere 
kans om remissie te bereiken. Een hogere VAS score op baseline 
was geassocieerd met de ernst van de niet-pijnlijke fysieke symp-
tomen en vorige depressieve episodes. De gemiddelde mentale 
gezondheidsscore (SF-36 MCS) nam toe tijdens follow-up, terwijl 
de gemiddelde fysische gezondheidsscore (SF-36 PCS) stabiel bleef.
Conclusie:
Artsen blijken geen onderscheid te maken tussen depressieve en 
angstsymptomen bij de opstart van antidepressieve medicatie. 
Angst blijkt een sterkere predictor dan depressie om antidepres-
sieve medicatie te starten.  De aanwezigheid van pijnlijke en niet 
pijnlijke somatische symptomen blijken voorspellers van de behan-
delrespons bij depressie.  
Trefwoorden: depressie; angst; observationele studie; ernst van 
pijn; interferentie van pijn met functioneren.
Samenvatting
Auteur correspondant :
Dr Katrien Schoevaerts
University Hospitals Gasthuisberg
University Psychiatric Centre KuLeuven, 
campus Leuven, Herestraat 49, 
3000 Leuven     Belgium
Email : Katrien.schoevaerts@med.kuleuven.be
